Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression
Cecilia Dallavalle, … , Carlo V. Catapano, Giuseppina M. Carbone
Cecilia Dallavalle, … , Carlo V. Catapano, Giuseppina M. Carbone
Published November 7, 2016
Citation Information: J Clin Invest. 2016;126(12):4585-4602. https://doi.org/10.1172/JCI86505.
View: Text | PDF
Research Article Oncology

MicroRNA-424 impairs ubiquitination to activate STAT3 and promote prostate tumor progression

  • Text
  • PDF
Abstract

Mutations and deletions in components of ubiquitin ligase complexes that lead to alterations in protein turnover are important mechanisms in driving tumorigenesis. Here we describe an alternative mechanism involving upregulation of the microRNA miR-424 that leads to impaired ubiquitination and degradation of oncogenic transcription factors in prostate cancers. We found that miR-424 targets the E3 ubiquitin ligase COP1 and identified STAT3 as a key substrate of COP1 in promoting tumorigenic and cancer stem-like properties in prostate epithelial cells. Altered protein turnover due to impaired COP1 function led to accumulation and enhanced basal and cytokine-induced activity of STAT3. We further determined that loss of the ETS factor ESE3/EHF is the initial event that triggers the deregulation of the miR-424/COP1/STAT3 axis. COP1 silencing and STAT3 activation were effectively reverted by blocking of miR-424, suggesting a possible strategy to attack this key node of tumorigenesis in ESE3/EHF–deficient tumors. These results establish miR-424 as an oncogenic effector linked to noncanonical activation of STAT3 and as a potential therapeutic target.

Authors

Cecilia Dallavalle, Domenico Albino, Gianluca Civenni, Jessica Merulla, Paola Ostano, Maurizia Mello-Grand, Simona Rossi, Marco Losa, Gioacchino D’Ambrosio, Fausto Sessa, George N. Thalmann, Ramon Garcia-Escudero, Andrea Zitella, Giovanna Chiorino, Carlo V. Catapano, Giuseppina M. Carbone

×

Figure 5

miR-424 targets the E3 ubiquitin ligase COP1, leading to multiple oncogenic TF activation.

Options: View larger image (or click on image) Download as PowerPoint
miR-424 targets the E3 ubiquitin ligase COP1, leading to multiple oncoge...
(A) Venn diagram of predicted targets (miRWalk) and genes repressed by miR-424 in RWPE1 cells. (B) Functional annotation analysis by DAVID of the putative miR-424 target genes. (C) Level of COP1 by qRT-PCR (top) and immunoblotting (bottom) in prostate cell lines. (D) Diagram of 3′-UTR COP1 reporter construct with WT and mutated (MUT) sequence of the miR-424 binding site (left) and relative luciferase activity (RLA) following transfection of miR-424 in LNCaP cells (right). (E) COP1, c-Jun, and ETV1 expression in RWPE1 cells following transient transfection of miR-424 and LNCaP cells stably overexpressing miR-424. Replicate samples were run on separate gels for blotting with the different antibodies. (F) COP1, c-Jun, and ETV1 expression following transfection of siRNAs targeting COP1 (siCOP1#1 and #2) or control siRNA (siGL3) in RWPE1 and LNCaP cells. (G) COP1, c-Jun, and ETV1 expression following transfection of Anti-424 or Scr in RWPE-ESE3kd and DU145 cells. (H–K) Immunoblot of COP1 (H), colony formation in soft agar (I), cell migration by WH (J), and SFE and representative images of spheroids (K), following knockdown of COP1 by siRNA (siCOP1#1) and control (siGL3) in RWPE1 cells. Data show mean ± SD of 3 independent experiments. *P < 0.05; **P < 0.01. Scale bar: 200 µm.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts